Multiple sclerosis: disease markers accelerate progress.
Fox
Robert J
RJ
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH, Cleveland, USA.
Rudick
Richard A
RA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D051017:Apoptosis Regulatory Proteins; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers; D001921:Brain / Q000473:pathology; D002465:Cell Movement / Q000187:drug effects; D006801:Humans; D008279:Magnetic Resonance Imaging; D008562:Membrane Glycoproteins / Q000235:genetics; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000473:pathology*; D000069442:Natalizumab; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D051017:Apoptosis Regulatory Proteins; D001323:Autoantibodies; D015415:Biomarkers; D008562:Membrane Glycoproteins; D000069442:Natalizumab; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha